Forum
Starting ART following cryptococcal meningitis:The optimal time has yet to be defined
Southern African Journal of HIV Medicine | Vol 14, No 3 | a61 |
DOI: https://doi.org/10.4102/sajhivmed.v14i3.61
| © 2013 T A Bicanic, J N Jarvis, A Loyse, T S Harrison
| This work is licensed under CC Attribution 4.0
Submitted: 12 December 2013 | Published: 17 September 2013
Submitted: 12 December 2013 | Published: 17 September 2013
About the author(s)
T A Bicanic, Cryptococcal Meningitis Group, Research Centre of Infection and Immunity, St George’s University of London, London, Cryptococcal Meningitis Group, Research Centre of Infection and Immunity, St George’s University of London, London, United Kingdom, United KingdomJ N Jarvis, Cryptococcal Meningitis Group, Research Centre of Infection and Immunity, St George’s University of London, London, United Kingdom; Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom, United Kingdom
A Loyse, Cryptococcal Meningitis Group, Research Centre of Infection and Immunity, St George’s University of London, London, United Kingdom, United Kingdom
T S Harrison, Cryptococcal Meningitis Group, Research Centre of Infection and Immunity, St George’s University of London, London, United Kingdom, United Kingdom
Abstract
Ever since the public sector rollout of antiretroviral therapy (ART) in 2004, the question of the optimal time to start ART following diagnosis of an opportunistic infection has aroused controversy among South African HIV clinicians and researchers.
Keywords
ART; antiretroviral therapy; cryptococcal meningitis;
Metrics
Total abstract views: 3666Total article views: 5938